Pharmaceutical giant Bayer is leaning on artificial intelligence to push forward its work in drug discovery, according to Procurement Magazine.
The report centers on Juergen Eckhardt, M.D., who serves as Head of Business Development and Licensing at Bayer. According to Procurement Magazine, Eckhardt is embracing new technology in the world of pharmaceuticals as the company looks to apply AI to the way it finds and develops new medicines.
The coverage, also surfaced through Google News and Bing News aggregators, frames Bayer's move as part of a broader shift in how large drugmakers approach research. Drug discovery has traditionally been slow, expensive and uncertain, with many candidate compounds failing before they ever reach patients. The promise of AI is that it can help researchers sift through vast amounts of biological and chemical data more quickly, potentially narrowing the search for viable treatments.
Beyond the involvement of Eckhardt and his focus on adopting new technology, the source material does not detail which specific AI tools Bayer is using, what diseases it is targeting, or what results the effort has produced so far.
Why it matters: when a company the size of Bayer publicly ties its drug-discovery strategy to AI, it signals that the technology is moving from experiment to mainstream practice in an industry whose breakthroughs directly affect patients.